Takeda Pharmaceutical Co. has agreed to a $2.4 billion settlement to resolve bladder cancer claims tied to its Type 2 diabetes drug Actos. The settlement will compensate an anticipated 9,000 claimants who filed federal and state lawsuits alleging they suffered from bladder cancer after taking Actos, says Beasley Allen lawyer Andy D. Birchfield, who is head of the firm’s Mass Torts Section. He serves on the Plaintiffs Steering Committee for the Actos multidistrict litigation (MDL) and was one of the signatories for the settlement agreement.
The settlement follows a record-setting $9 billion jury verdict one year ago in the MDL bellwether case before Judge Rebecca F. Doherty, who is overseeing the consolidated litigation in the United States District Court, Western District of Louisiana. The lead trial lawyer in that case was Mark Lanier from Houston, Texas.
“This is a great settlement for Actos claimants and I am excited that victims will receive good, fair compensation for their injuries,” Birchfield said. “This settlement program has been carefully constructed to fairly compensate claimants based upon the extent of their injuries and their cumulative exposure to Actos, taking into account other risk factors that could have contributed to their injuries. This is a good day for the hundreds of Actos clients represented by Beasley Allen, and we are grateful to have been able to obtain such a positive resolution on their behalf.”
In 2011, the Food and Drug Administration (FDA) issued a safety communication regarding the potential link between Actos and bladder cancer, which the lawsuits claim was seven years after the company first discovered a link between Actos and bladder cancer.